[1]金秋晨,张 宸,陈永法.抗肿瘤药物联合疗法价值归因探索[J].卫生经济研究,2023,40(10):74-78.
　JIN Qiuchen,ZHANG Chen,CHEN Yongfa.Study on the Value Attribution of Antitumor Drug Combination Therapy[J].Journal Press of Health Economics Research,2023,40(10):74-78.
点击复制

抗肿瘤药物联合疗法价值归因探索
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年10期
页码:
74-78
栏目:
经济学评价
出版日期:
2023-09-28

文章信息/Info

Title:
Study on the Value Attribution of Antitumor Drug Combination Therapy
作者:
金秋晨1; 张 宸1; 陈永法1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
JIN Qiuchen;  ZHANG Chen;  CHEN Yongfa
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
联合疗法; 卫生技术评估; 价值归因; 抗肿瘤药物
Keywords:
combination therapy;  health technology assessment;  value attribution;  antitumor drugs
分类号:
R956
文献标志码:
A
摘要:
目的：准确评估抗肿瘤药物联合疗法及组成联合疗法的各药物价值。方法：详细介绍价值归因的原理及使用条件。结果：总结基于各单药疗效比值的归因、基于边际价值的归因和分段分配价值归因三种基本价值归因类型及相关变型，在此基础上进一步对比分析不同情况下各价值归因方法的结果，给出选择思路。结论：价值归因应用具有独特优势，也存在局限性，应全方位收集证据，进一步完善方法，权衡各方利益谨慎选择适用方法，最终构建适合我国的特色价值归因体系。
Abstract:
Objective To accurately evaluate anti-tumor drug combination therapy and the value of various drugs those make up the combination therapy. Methods The principle and usage conditions of value attribution were introduced in detail. Results This article summarized three basic types of value attribution, including attribution based on the benefit ratio of each single drug, attribution based on marginal value, and attribution based on segmented allocation value, as well as related variants. On this basis, this article further compared and analyzed the results of various value attribution methods in different situations, and provided selection ideas. Conclusion The application of value attribution has unique advantages and limitations. It is necessary to collect evidence from all aspects, further improve methods, weigh the interests of all parties, and carefully choose applicable methods, ultimately construct a unique value attribution system suitable for China.

参考文献/References:

[1] NICE health technology evaluation topic selection: the manual[EB/OL].(2022-01-31)[2023-02-14].https://www.nice.org.uk/process/pmg37/chapter.
[2] Danko D,Blay J Y,Garrison L P.Challenges in the value assessment,pricing and funding of targeted combination therapies in oncology[J].Health Policy,2019,123(12):1230-1236.
[3] 国家药品监督管理局药品审评中心.抗肿瘤药联合治疗临床试验技术指导原则[EB/OL].（2020-12-31）[2023-02-14].https://www.cde.org.cn/main/ news/viewInfoCommon/ef7bfde96c769308a dd080bb7ab2f538e.
[4] Kim T K,Vandsemb E N,Herbst R S,et al.Adaptive immune resistance at the tumour site:mechanisms and therapeutic opportunities[J].Nature Reviews Drug Discovery,2022,21(7):529-540.
[5] 刘国恩，吴晶，谢锋，等.中国药物经济学评价指南导读（2022） [M].北京:中国市场出版社，2022.
[6] Towse A,Lothgren M,Bruce A,et al.Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies[EB/OL].(2022-11-30) [2023-02-14].https://www.ohe.org/wp-content/uploads/2023/01/Towse-Lothgren-et-al.-2022.pdf.
[7] Wolchok J D,Chiarion-Sileni V,Gonzalez R,et al.Long-Term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma[J].J Clin Oncol,2022,40(2):127-137.
[8] Jiao B S,Garrison L P.The challenge of value-based pricing in combination therapy:the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer [J].Expert Review of Pharmacoeconomics & Outcomes Research,2021,21(3):497-504.
[9] Briggs A H,Doyle A,Schneider J,et al.An Attribution of Value Framework for Combination Therapies[C].2021.
[10] Latimer N R,Towse A,Henshall C.Not cost-effective at zero price:valuing and paying for combination therapies in cancer[J].Expert Review of Pharmacoeconomics & Outcomes Research,2021,21(1/3):331-334.
[11] 管欣，王璐颖，李洪超.药物经济学评价中“免费仍不经济”类结果的原因分析[J].中国药房，2021，32（18）：2242-2247.
[12] Latimer N R,Pollard D,Towse A,et al.Challenges in valuing and paying for combination regimens in oncology.Report of an international workshop[J].BMC Health Serv Res,2021,21(1):412.
[13] Garside R,Pitt M,Erson R,et al.The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis:a systematic review and economic evaluation[J].Health Technol Assess,2007,11(18):1-167.

相似文献/References:

[1]黄 理,路 云,段承阿鑫.卫生技术评估在高值医用耗材供应保障中的应用价值及其实现[J].卫生经济研究,2018,(10):10.
　HUANG Li,LU Yun,DUAN Cheng-a-xin.The Application Value and Its Realization of Health Technology Assessment in the Supply Security of High-value Medical Consumables[J].Journal Press of Health Economics Research,2018,(10):10.
[2]金春林,王海银,孙 辉,等.价值医疗的概念、实践及其实现路径[J].卫生经济研究,2019,(02):6.
　JIN Chun-lin,WANG Hai-yin,SUN Hui,et al.The Concept, Progress and Practice Path of Value-based healthcare[J].Journal Press of Health Economics Research,2019,(10):6.
[3]傅 卫,赵 琨.中国卫生技术评估的发展与挑战[J].卫生经济研究,2019,(03):3.
　FU Wei,ZHAO Kun.Development and Challenges of China's Health Technology Assessment[J].Journal Press of Health Economics Research,2019,(10):3.
[4]张 宸,金秋晨,陈永法.儿童药卫生技术评估的特殊性——以英国NICE儿童药评估为例[J].卫生经济研究,2021,38(11):51.
　ZHANG Chen,JIN Qiu-chen,CHEN Yong-fa.Particularity of Health Technology Assessment for Children's Drug——Taking NICE Children's Drug Assessment as an Example[J].Journal Press of Health Economics Research,2021,38(10):51.
[5]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(10):62.

更新日期/Last Update: 2023-09-28